LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement